July 5, 2005 -- Stocks charged higher across the board on Tuesday, the first day of post-holiday trading. Biotech did well, with the Centient Biotech 200? gaining more than 35 points to close at 3396.61, a rise of 1.03%. The S&P 500 was up .88%, and Nasdaq climbed 1.04%, taking the honors for biggest gain on the day. A Human Genome Science cancer drug did well in a Phase II test, Hollis-Eden got an FDA go-ahead for a Phase I trial of an Acute Radiation Syndrome drug, Boston Scientific won a stent patent dispute over Johnson & Johnson, Baush & Lomb bought a Chinese ophthalmic company for $200 million, and Vasogen said its inflammation disease treatment passed its Phase I trial.
